Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?
TUESDAY, July 20, 2021 -- Women on hormone replacement therapy (HRT) for menopause go on to have a 58% lower risk of Alzheimer's disease and other neurodegenerative conditions, a new study finds. Although the study wasn't designed to prove cause and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2021 Category: General Medicine Source Type: news

Tool helps predict who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 12, 2021 Category: Universities & Medical Training Source Type: news

Tool helps predicts who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 9, 2021 Category: Universities & Medical Training Source Type: news

' Treat Youth With Gender Dysphoria as Individuals'' Treat Youth With Gender Dysphoria as Individuals '
Last week the Tavistock appealed a High Court ruling that adolescents with gender dysphoria were unlikely to fully understand the consequences of hormone therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Consumer Health: Hormone therapy for people who are transgender
Transgender is an umbrella term used to capture the spectrum of gender identity and gender-expression diversity. Gender identity is the internal sense of being male, female, neither or both. Gender expression involves the expression of a person's gender identity through social roles, appearance and behaviors. Most children categorize their own gender by 3. However, because [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 24, 2021 Category: Databases & Libraries Source Type: news

Hormone Pellet Safety Data'Not Very Reassuring at All' for Women Hormone Pellet Safety Data'Not Very Reassuring at All' for Women
Women who receive pellet hormonal therapy may be significantly more likely to have side effects compared with women who receive FDA-approved hormonal treatments.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 18, 2021 Category: Primary Care Tags: Ob/Gyn & Women ' s Health News Source Type: news

AHA News: At 17, He Received a New Heart. By 23, He Began Transitioning.
FRIDAY, June 18, 2021 (American Heart Association News) -- For most transgender people, starting hormone therapy requires a therapist's approval. As the recipient of a new heart, Maddox Jones also needed his transplant team's OK. " It was a long and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 18, 2021 Category: General Medicine Source Type: news

When Does Hormone Therapy Fail for Prostate Cancer?
Title: When Does Hormone Therapy Fail for Prostate Cancer?Category: Health and LivingCreated: 6/9/2021 12:00:00 AMLast Editorial Review: 6/9/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 9, 2021 Category: Cancer & Oncology Source Type: news

Using IGF-I to Monitor Long-Acting Growth Hormone Therapy Using IGF-I to Monitor Long-Acting Growth Hormone Therapy
What is the optimal timing of IGF-I measurement for the monitoring of long-acting growth-hormone therapy? This commentary explores the issues.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 7, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Hormone Therapy, Mammographic Density and Breast Cancer Risk Hormone Therapy, Mammographic Density and Breast Cancer Risk
What have we learned about the joint effect of menopausal hormone therapy and mammographic density on the risk for breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Challenging Gender-Affirming Hormone Therapy Prescribing Challenging Gender-Affirming Hormone Therapy Prescribing
This commentary explores the findings from a new study that challenge standard prescribing recommendations for gender-affirming hormone therapy.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Researchers aim to modify fragmented health care system to reduce HIV incidence among trans women
(University of Texas Health Science Center at Houston) There are an estimated one-million transgender adults living in the US and an estimated 14% of transgender women are living with HIV. Researchers at UTHealth are studying if a combination intervention that combines HIV prevention services and hormonal therapy, supported by peer health navigation, will reduce HIV acquisition among this patient population. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 21, 2021 Category: Infectious Diseases Source Type: news

CDK inhibitors may improve immune therapy effectiveness for recurrent breast cancer
(Ohio State University Wexner Medical Center) A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers atThe Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2021 Category: International Medicine & Public Health Source Type: news

Success in LGBTQ+ Medicine Requires Awareness of Risk Success in LGBTQ+ Medicine Requires Awareness of Risk
Cross-sex hormone therapy is not without risks, said Dr Megan McNamara, including'very high'risks of erythrocytosis among transgender men and venous thromboembolic disease among transgender women.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 4, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Mayo Clinic Minute: Lifestyle changes to manage menopause symptoms
The average healthy woman begins menopause at 51, though some women will begin in their 40s or in their late 50s. It's a natural biological process that marks the time a woman ends her menstrual cycle. Mood swings, hot flashes and difficulty sleeping are common symptoms that can be effectively managed with hormone therapy. Lifestyle [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 3, 2021 Category: Databases & Libraries Source Type: news

Growth Hormone Therapy in Adults With Prader-Willi Syndrome Growth Hormone Therapy in Adults With Prader-Willi Syndrome
Should growth hormone therapy have a role in the management of adults with Prader-Willi syndrome?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Associations of Endometriosis and HT With Hyperlipidemia Associations of Endometriosis and HT With Hyperlipidemia
Are endometriosis and related use of hormone therapy associated with an increased risk of developing hyperlipidemia?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2021 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

AHA Offers Guidance for CVD Risk in Breast, Prostate Cancer
Patients with breast, prostate cancer who are receiving hormonal therapy more likely to develop cardiovascular risk factors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 26, 2021 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Oncology, Pharmacy, Urology, Journal, Source Type: news

Close monitoring for heart risk needed if breast, prostate cancer treatment includes hormones
(American Heart Association) Patients with breast and prostate cancers who are treated with hormonal therapies have an increased risk of heart attack and/or stroke as they age.The increased likelihood of a heart attack or stroke is greater in patients who already have two or more cardiovascular risk factors such as high blood pressure, high cholesterol, obesity, smoking or a family history of heart disease or stroke.The longer the duration of hormonal therapy, the higher the risk of cardiovascular disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news

Transgender Hormone Therapy Linked to Blood Pressure Changes Transgender Hormone Therapy Linked to Blood Pressure Changes
Blood pressure elevations in transgender males and a subset of transgender females are seen before and soon after gender-affirming hormone therapy initiation.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 19, 2021 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Gender-Affirming Hormone Therapy Tied to Systolic BP Changes
MONDAY, April 19, 2021 -- Within two to four months of starting gender-affirming hormone therapy (GAHT), transfeminine adults have lower mean systolic blood pressure and transmasculine adults have higher mean systolic blood pressure, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2021 Category: Pharmaceuticals Source Type: news

Hormone Treatments May Raise Blood Pressure in Transgender People
MONDAY, April 19, 2021 -- Monitoring blood pressure is important for transgender people, according to new research, which found changes in systolic blood pressure after the start of gender-affirming hormone therapy. Transgender men and transgender... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2021 Category: General Medicine Source Type: news

Gender-affirming hormone therapy may increase risk of high blood pressure
(Beth Israel Deaconess Medical Center) In the largest and longest observational study of its kind, physician-researchers from Beth Israel Deaconess Medical Center (BIDMC) found that gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2021 Category: International Medicine & Public Health Source Type: news

This Femtech Company Is Pioneering Mucus Engineering As A New Alternative To Hormonal Birth Control
Cirqle Biomedical is a startup pioneering mucus engineering as a new alternative to hormonal birth control, based in Copenhagen, and its team recently demonstrated the first novel and effective approach to contraception since hormonal therapy was introduced more than 60 years ago. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 14, 2021 Category: Pharmaceuticals Authors: Marija Butkovic, Contributor Tags: ForbesWomen /forbeswomen Leadership /leadership Innovation /innovation Healthcare /healthcare Source Type: news

Benefits and Risks of Menopausal HT Among Women 50-59 Benefits and Risks of Menopausal HT Among Women 50-59
This report analyzes additional years of follow-up from the Women's Health Initiative hormone therapy trials, with a focus on participants 50-59 years of age. Does the new data change recommendations?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2021 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

CTC mutations may predict outcomes in some castrate-resistant prostate cancer patients
(American Association for Cancer Research) Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 26, 2021 Category: Cancer & Oncology Source Type: news

Hormone Therapy May Reduce Nocturia After Menopause
TUESDAY, March 23, 2021 -- The percentage of postmenopausal women experiencing nocturia two or more times per night was lower among those who selected systemic hormone treatment compared with no treatment, according to a study published online March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2021 Category: Pharmaceuticals Source Type: news

Prostate cancer uses metabolic switch to thrive after hormone therapy
(Duke University Medical Center) Studying the cellular metabolism of prostate cancer, a team of Duke Health-led researchers identified a key reason hormone therapies eventually fail, while also laying out a way to bypass the problem using an entirely new therapeutic approach. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 22, 2021 Category: Cancer & Oncology Source Type: news

Hormone therapy shown to reduce effects of nocturia in postmenopausal women
(The North American Menopause Society (NAMS)) CLEVELAND, Ohio (March 17, 2021)--As women age, they are more likely to wake up in the middle of the night to pass urine. The loss of estrogen during the menopause transition accelerates this problem, which is known as nocturia. A new study evaluated the effectiveness of different hormone therapies in managing the frequency of nocturia. Study results are published online today inMenopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 17, 2021 Category: International Medicine & Public Health Source Type: news

Hormone Therapy and Sexual Function During Menopausal Transition Hormone Therapy and Sexual Function During Menopausal Transition
Does hormonal therapy have a positive impact on sexual function in perimenopausal women?Menopause (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

ACOG Advises on Care for Transgender Patients ACOG Advises on Care for Transgender Patients
The committee opinion provides guidance for ob-gyns. on topics including inclusivity, routine screening, fertility and reproductive issues, hormone therapy, medication use, and surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

Molecular imaging determines effectiveness of novel metastatic breast cancer treatment
(Society of Nuclear Medicine and Molecular Imaging) Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news

Genomic test helps estimate risk of prostate cancer metastasis, death
(Johns Hopkins Medicine) A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Imaging identifies breast cancer patients unlikely to benefit from hormone therapy
(Washington University School of Medicine) Hormone therapy can be very effective for so-called estrogen receptor-positive breast cancer. But it only works for a little more than half of women who receive the treatment. In a small study, researchers at Washington University School of Medicine in St. Louis found that women whose tumors did not respond to a one-day estrogen challenge did not benefit from hormone therapy. The findings could help doctors choose treatments most likely to help their patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2021 Category: International Medicine & Public Health Source Type: news

No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery
Transgender women can safely maintain their estrogen hormone therapy during gender-affirming surgery without an increased risk of venous thromboembolism (VTE), according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news

Estrogen Therapy Need Not Stop for Gender - Affirming Surgery
Authors find that perioperative venous thromboembolism rarely occurs, regardless of suspension of hormone therapy prior to surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 19, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Journal, Source Type: news

Estrogen Therapy Need Not Stop for Gender-Affirming Surgery
TUESDAY, Jan. 19, 2021 -- For transgender and gender nonbinary (TGNB) patients undergoing primary vaginoplasty, perioperative venous thromboembolism (VTE) occurs rarely, regardless of whether hormone therapy is suspended prior to surgery, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2021 Category: Pharmaceuticals Source Type: news

What Is Hormone Therapy Used For
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 12, 2021 Category: General Medicine Source Type: news

Sexual dysfunction hits some women harder than others as they age
(The North American Menopause Society (NAMS)) Sexual dysfunction often accompanies the menopause transition. Yet, not all women experience it the same. A new study identified the determinants that affect a woman's risk of sexual dysfunction and sought to determine the effectiveness of hormone therapy in decreasing that risk and modifying sexual behavior. Study results are published online in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 6, 2021 Category: International Medicine & Public Health Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs. The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer. Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news

New oral hormone drug for prostate cancer
The Food and Drug Administration has approved the use of a new oral hormone therapy drug, Relugolix, for treating advanced prostate cancer in men.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 22, 2020 Category: Endocrinology Source Type: news

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer
MONDAY, Dec. 21, 2020 -- Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. Food and Drug Administration announced Friday. As opposed to currently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
Today, the FDA approved the first oral hormone therapy for treating advanced prostate cancer. This therapy may eliminate some patients ’ need to visit the clinic for treatments that require administration by a health care provider. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news